



FIG S1. pTIC10a-*phoU1* leaky expression. RNA was extracted from the indicated strains grown to mid-logarithmic phase in complete 7H9 medium supplemented with the indicated anhydrotetracycline (ATC) concentration. Quantitative RT-PCR was performed to determine abundance of the *phoU1* transcripts relative to the *sigA* housekeeping control. Results are the mean of three biological replicates \pm standard deviations. Asterisks indicate statistically significant differences compared to the *mc²155* control: * $P < 0.05$.

Table S1. Plasmids used in this study.

Plasmid	Genotype	Reference
pCR2.1 TOPO	PCR cloning vector Amp ^R Kan ^R	Invitrogen
pJG1100	Allelic exchange suicide vector Kan ^R Hyg ^R <i>sacB</i>	(1)
pBE101	pJG1100::Δ <i>phoU1</i> (<i>Msmeg_5776</i>), Kan ^R , Hyg ^R , <i>sacB</i>	This work
pBE102	pJG1100::Δ <i>phoU2</i> (<i>Msmeg_1605</i>), Kan ^R , Hyg ^R , <i>sacB</i>	This work
pMV261	Episomal vector with <i>hsp60</i> promoter Kan ^R	(2)
pMV <i>phoU1</i>	pMV261:: <i>phoU1</i> , Kan ^R	This work
pMV <i>phoU2</i>	pMV261:: <i>phoU2</i> , Kan ^R	This work
pTIC10a	Integrating vector with codon-optimized TetR, P _{<i>smyc</i>} -TetO, Kan ^R	(3)
pTIC <i>phoU1</i>	pTIC10a:: <i>phoU1</i> , Kan ^R	This work
pJT6a	Integrating vector with codon-optimized TetR, P _{<i>smyc</i>} -TetO, Hyg ^R	(4)
pJT <i>phoU1</i>	pJT6a:: <i>phoU1</i> , Hyg ^R	This work

1. **Kirksey MA, Tischler AD, Siméone R, Hisert KB, Uplekar S, Guilhot C, McKinney JD.** 2011. Spontaneous phthiocerol dimycocerosate-deficient variants of *Mycobacterium tuberculosis* are susceptible to gamma interferon-mediated immunity. Infect Immun **79**:2829-2838.
2. **Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, Jr., Bloom BR.** 1991. New use of BCG for recombinant vaccines. Nature **351**:456-460.
3. **Glover RT, Kriakov J, Garforth SJ, Baughn AD, Jacobs WRJ.** 2007. The two-component regulatory system *senX3-regX3* regulates phosphate-dependent gene expression in *Mycobacterium smegmatis*. J Bacteriol **189**:5495-5503.
4. **Rosen BC, Dillon NA, Peterson ND, Minato Y, Baughn AD.** 2017. Long-chain fatty acyl coenzyme A ligase FadD2 mediates intrinsic pyrazinamide resistance in *Mycobacterium tuberculosis*. Antimicrob Agents Chemother **61**:e02130-16.

Table S2. Oligonucleotide primers used for cloning or strain construction in this study.

Name	Purpose	Sequence (5'-3') ^a
1605F1	Upstream $\Delta phoU2$	ATGCTTAATTAAACACTGCCCTGCTAAC
1605R1	Upstream $\Delta phoU2$	ATGCCCTAGGAGCTCG CAT CGCCCATGAC
1605F2	Downstream $\Delta phoU2$	GCATCCTAGGCTCGC TGATT ACCGGCTAGC
1605R2	Downstream $\Delta phoU2$	ATGCGGCGGCCGTTGATGCGCTCTGCGA ACT
5776F1	Upstream $\Delta phoU1$	GCATTAAATTAA ACCG CATCACGTTCGTCACC AT
5776R1	Upstream $\Delta phoU1$	ATGCCCTAGGATGGTACTGGAT CCG CAT GCA
5776F2	Downstream $\Delta phoU1$	GCATCCTAGGAAGGTAC AC ACGCAGCAG
5776R2	Downstream $\Delta phoU1$	ATGCGGCGGCC CC CTTGGT GAGGTTGGT GAG
1605F3	Check $\Delta phoU2$	GGAAACAGCTGCTGCGAAC
1605R3	Check $\Delta phoU2$	CGAGCTTTCGGCAA ACT CGA
1605F4	Check $\Delta phoU2$	GGATGGGTAC CT ACGT CC TA
1605R4	Check $\Delta phoU2$	CCTGGTGAT CT G CTCC GTAA
5776F3	Check $\Delta phoU1$	ACCAAGGAT CT CG GG AC CT C
5776R3	Check $\Delta phoU1$	CGACGGGAAG CT CG AT CT CC
5776F4	Check $\Delta phoU1$	GGT GTT CAC CG CC TA AT CT GG
5776R4	Check $\Delta phoU1$	CGCGACT CC CT GAT GC GT A
1605CF	pMV $phoU2$ cloning	ATGAATT CGG TAC CT ACG T C CT CAT CC GG
1605CR	pMV $phoU2$ cloning	ATAAG CTT CT GG T GAT CT G CT CC G T ACC
5776CF	pMV $phoU1$ cloning	ATGAATT CC AC CA CG AG CT CG T G A C T G
5776CR	pMV $phoU1$ cloning	ATAAG CTT CC GAT CAG CC GT AG GT CA
TIC5776F	pTIC10a- $phoU1$ cloning	ATAAG CTT CC AC AG CA AG CT CG T G A C T G
TIC5776R	pTIC10a- $phoU1$ cloning	ATGAATT CC CG AT CAG CC GT AG GT CA
pTfor	Check plasmid switch	CAT CCC GG CG TT GAT CT GT G
pTIC6a_R	Check plasmid switch	TTT T CT TA AG G AC CA AG AC G T T CC G T
1387F2	Verify point mutation	TGCGACAT CTT CC CT GG TG
1387R2	Verify point mutation	AGCACGTT GC GC CAT CAGC
DM504_pstSF	Verify point mutation	ATGAGCGGCGA AT ACG TT GC
DM504_pstSR	Verify point mutation	GGGAAC CT GT CG GT CAT GT G
DM518_pstBF	Verify point mutation	CG CT AC GC CT CAT CC TC G

DM518_pstBR	Verify point mutation	GTCCATGGTGGATGCCGG
DM521_pstBF	Verify point mutation	GATCGCCCTGCTGAATGTCG
DM521_pstBR	Verify point mutation	GAAGTCGCCGTGGAAC
DM625_pstSF	Verify point mutation	TACGTTGCCGGGGAGTCTG
DM625_pstSR	Verify point mutation	GTCACTGTTATCCCGTCGGG
DM664_pstCF	Verify point mutation	GCCCAACGCCTCAAAGAGC
DM664_pstCR	Verify point mutation	GTGTGGTCGGTCAGCCTG

^aRestriction enzyme sites used for cloning are underlined. Start and stop codons in primers used for construction of in-frame deletions are indicated in bold.

Table S3. Oligonucleotides used for qRT-PCR.

Gene	F primer sequence 5'-3'	R primer sequence 5'-3'
<i>Msm_sigA</i>	CCAAGGGCTACAAGTTCTCG	CCATGTGCACCGGGATAC
<i>Msm_pstS</i>	GGCGTCGACAAGCTGGTACT	GGTGATCTGGCCTTGAAGA
<i>Msm_regX3</i>	TCCC GTGCGCATGGA	GGCAACGTGATCGGTTCAC
<i>Msm_phoA</i>	CGCAGAAGGCCATCGATCT	ATCGACGCGCCCTCCA
<i>Msm_1605</i>	GCAGACGGCGTTCAAAC	ACGACCATA CGCAGCTCACT
<i>Msm_5776</i>	AGAGGTCAACGGCTACTTCG	CGTCGTCTTCCTCCTGGAT